BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38493671)

  • 1. MDSC-targeting gold nanoparticles enhance PD-1 tumor immunotherapy by inhibiting NLRP3 inflammasomes.
    Zhu Y; Chen P; Hu B; Zhong S; Yan K; Wu Y; Li S; Yang Y; Xu Z; Lu Y; Ouyang Y; Bao H; Gu W; Wen L; Zhang Y
    Biomaterials; 2024 Jun; 307():122533. PubMed ID: 38493671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression.
    Papafragkos I; Grigoriou M; Boon L; Kloetgen A; Hatzioannou A; Verginis P
    Front Immunol; 2022; 13():889075. PubMed ID: 36032139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
    Tengesdal IW; Menon DR; Osborne DG; Neff CP; Powers NE; Gamboni F; Mauro AG; D'Alessandro A; Stefanoni D; Henen MA; Mills TS; De Graaf DM; Azam T; Vogeli B; Palmer BE; Pietras EM; DeGregori J; Tan AC; Joosten LAB; Fujita M; Dinarello CA; Marchetti C
    Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.
    Koehn BH; Saha A; McDonald-Hyman C; Loschi M; Thangavelu G; Ma L; Zaiken M; Dysthe J; Krepps W; Panthera J; Hippen K; Jameson SC; Miller JS; Cooper MA; Farady CJ; Iwawaki T; Ting JP; Serody JS; Murphy WJ; Hill GR; Murray PJ; Bronte V; Munn DH; Zeiser R; Blazar BR
    Blood; 2019 Nov; 134(19):1670-1682. PubMed ID: 31533918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
    Theivanthiran B; Evans KS; DeVito NC; Plebanek M; Sturdivant M; Wachsmuth LP; Salama AK; Kang Y; Hsu D; Balko JM; Johnson DB; Starr M; Nixon AB; Holtzhausen A; Hanks BA
    J Clin Invest; 2020 May; 130(5):2570-2586. PubMed ID: 32017708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Penetrating Nanoparticles Activate the Inflammasome to Enhance Antibody Production by Targeting Microtubule-Associated Protein 1-Light Chain 3 for Degradation.
    Zhu M; Du L; Zhao R; Wang HY; Zhao Y; Nie G; Wang RF
    ACS Nano; 2020 Mar; 14(3):3703-3717. PubMed ID: 32057231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-27 regulates NLRP3 inflammasome activation of MDSCs in experimental Sjögren's syndrome.
    Xia X; Long Q; Zha J; Jiang T; Guo J; Jiang B; Li X; Yao G
    Int Immunol; 2023 Nov; 35(11):531-542. PubMed ID: 37756640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells.
    van Deventer HW; Burgents JE; Wu QP; Woodford RM; Brickey WJ; Allen IC; McElvania-Tekippe E; Serody JS; Ting JP
    Cancer Res; 2010 Dec; 70(24):10161-9. PubMed ID: 21159638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candida tropicalis induces NLRP3 inflammasome activation via glycogen metabolism-dependent glycolysis and JAK-STAT1 signaling pathway in myeloid-derived suppressor cells to promote colorectal carcinogenesis.
    Zhang Z; Chen Y; Yin Y; Chen Y; Chen Q; Bing Z; Zheng Y; Hou Y; Shen S; Chen Y; Wang T
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109430. PubMed ID: 36384075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.
    Chen L; Huang CF; Li YC; Deng WW; Mao L; Wu L; Zhang WF; Zhang L; Sun ZJ
    Cell Mol Life Sci; 2018 Jun; 75(11):2045-2058. PubMed ID: 29184980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
    Guo B; Fu S; Zhang J; Liu B; Li Z
    Sci Rep; 2016 Oct; 6():36107. PubMed ID: 27786298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactive oxygen species trigger NF-κB-mediated NLRP3 inflammasome activation induced by zinc oxide nanoparticles in A549 cells.
    Liang X; Zhang D; Liu W; Yan Y; Zhou F; Wu W; Yan Z
    Toxicol Ind Health; 2017 Oct; 33(10):737-745. PubMed ID: 28870124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression.
    Tengesdal IW; Dinarello A; Powers NE; Burchill MA; Joosten LAB; Marchetti C; Dinarello CA
    Front Immunol; 2021; 12():661323. PubMed ID: 34531850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production.
    Yu X; Lan P; Hou X; Han Q; Lu N; Li T; Jiao C; Zhang J; Zhang C; Tian Z
    J Hepatol; 2017 Apr; 66(4):693-702. PubMed ID: 28027970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye.
    Zheng Q; Ren Y; Reinach PS; She Y; Xiao B; Hua S; Qu J; Chen W
    Exp Eye Res; 2014 Aug; 125():1-8. PubMed ID: 24836981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
    Bruchard M; Mignot G; Derangère V; Chalmin F; Chevriaux A; Végran F; Boireau W; Simon B; Ryffel B; Connat JL; Kanellopoulos J; Martin F; Rébé C; Apetoh L; Ghiringhelli F
    Nat Med; 2013 Jan; 19(1):57-64. PubMed ID: 23202296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes.
    Ballbach M; Hall T; Brand A; Neri D; Singh A; Schaefer I; Herrmann E; Hansmann S; Handgretinger R; Kuemmerle-Deschner J; Hartl D; Rieber N
    J Innate Immun; 2016; 8(5):493-506. PubMed ID: 27351923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
    Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.